In a new webinar, Genoa Directors of Operations Joseph Pellerito and Katie Lozano share how organizations are addressing risks associated with transitions of care through unique partnerships and programs to address barriers to care, medication adherence and more.
To learn more about how Genoa can help you and those you serve, contact us today.
On January 21, 2025, the FDA announced the approval of Spravato® nasal spray as a monotherapy treatment for treatment-resistant depression (TRD), making this medication the first and only monotherapy option...
“I’ve always expressed myself through my art and learned to use my creativity to inspire others”, says Genoa Healthcare 2024 Art Celebration participant Shanelle G. Genoa’s annual Art Celebration invites...
Adolescents with treatment-resistant depression (TRD) often struggle with a lack of effective treatment options. While ketamine has been shown to help improve outcomes for adults living with major depressive disorder...
By Reena Neumann, PharmD, MBA Since January 1, 2024, the Centers for Medicare & Medicaid Services (CMS) has required that clinics provide outcomes data reporting to secure federal funding through...